WHO: Indian strain of COVID-19 resistant to antibodies
Mutations of the Indian strain of COVID-19 indicate its high infectivity and resistance to antibodies in both those who have been ill and vaccinated, the World Health Organization reported.
New varieties of the virus have been discovered in India, including B.1.617. It is a variant with mutations E484Q and L452R that was first identified in India from samples collected on December 1, 2020.
According to preliminary research results, the L452R mutation may interfere with the effectiveness of certain monoclonal antibody treatments. E484Q can neutralize antibodies. Thus, the antibodies that have appeared in a person who has recovered from COVID-19 will not help in the fight against Indian mutations.
Moreover, the new strain is also thought to be highly virulent, which means it is more likely to infect and cause disease.
WHO experts have not yet figured out what influenced the virus mutations in India. One of the factors could be the holding of mass events that increased its spread, as well as the mitigation of antiquated measures in the country.




















AraratBank at Leasing EXPO 2026: Special Leasing Offer for Energy-Efficient Equipment
Unibank to participate in Leasing Expo 2026 with a special offer
AraratBank in Lori: Competitive Solutions for Business and Economic Development
IDBank Participates in Regional Conference of the Union of Banks of Armenia, Presenting Innovative T...
Converse Bank Receives STP Excellence Award Once Again
IDBank Participates in Regional Conference of the Union of Banks of Armenia
The Power of One Dram April Beneficiary: Davitbek Games NGO
Ucom and Impact Hub Yerevan Announce the Third Year of Green Innovation Fellowship
Up to 25% idcoin When Buying Airline Tickets with IDBank Premium Cards
Team Holding: The second phase of the placement of USD-denominated bonds has been completed. Underwr...